A dual-agonist peptide construct designed with bifunctional binding capabilities targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor systems. The molecule’s architecture enables simultaneous engagement of two distinct receptor populations, producing additive or synergistic metabolic effects through parallel signaling mechanisms. Demonstrates enhanced potency in modulating energy homeostasis compared to single-target compounds.